Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities – a register-based retrospective cohort study in Finland

Table 2 Proportion of use of glucose lowering medication by different patient group

	only T2D (n = 4440)			T2D + CVD (n = 2544)			T2D + AMD (n = 942)			T2D + CVD + AMD (n = 503)
	2011-12	2015-16	P-value	2011-12	2015-16	P-value	2011-12	2015-16	P-value	2011-12	2015-16	P-value
Medication group:
No medication	11	9	< 0.001	12	11	0.098	11	10	0.722	11	14	0.047
Metformin only	38	30	< 0.001	32	24	< 0.001	37	28	< 0.001	31	23	< 0.001
Metformin and/or other non-insulin medication	23	27	< 0.001	20	22	0.032	21	24	0.018	18	21	0.106
Combination of insulin and non-insulin medication	23	30	< 0.001	28	34	< 0.001	26	31	< 0.001	32	33	0.083
Only Insulin therapy	5	4	0.241	8	9	0.306	6	6	0.758	8	11	0.042

P-value from the logistic regression models with generalized estimating equations (GEE) for the changes in the use of glucose lowering medications from baseline (2011-12) to follow-up (2015-16) by different patient groups. Adjustment for age and sex did not change the P-value. CVD = cardiovascular disease (I20-I25, I46, I48, I50, I63-I66 (except I63.6) and G45), AMD = any mental disorder (ICD-10 code F00-F03, F20-F48 & G30)

ISSN: 2731-4553